ClinicalTrials.Veeva

Menu
P

Pacific Arthritis Care Center | Los Angeles, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

PRA023
MK-7240
Tulisokibart
HZN-825
MK-7240-007
0

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 4 total trials

A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial. Participants will be screened within 6 weeks prior to the Bas...

Enrolling
Diffuse Cutaneous Systemic Sclerosis
Sclerosis, Systemic
Drug: Placebo
Drug: HZN-825 QD

The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.

Enrolling
Diffuse Cutaneous Systemic Sclerosis
Interstitial Lung Disease
Diagnostic Test: Companion diagnostic ( CDx)
Drug: Placebo

Trial sponsors

Amgen logo
P
The University of Alabama at Birmingham logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems